AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03026738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior mesh rectopexy
Description: fixation of the rectum anteriorly using laparosopy and polypropylene mesh
Study NCT03026738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic posterior mesh rectopexy
Description: fixation of the rectum posteriorly using laparosopy and polypropylene mesh
Study NCT03026738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polypropylene mesh
Description: A strip of polypropylene mesh will be introduced and sutured.
Study NCT03707275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexa+
Description: Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
Study NCT03707275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Arm
Description: This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
Study NCT01143740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: orally day 1-10 each 28-day cycle, 3 cycles
Study NCT00129662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial action plan
Study NCT02672020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omics identity card
Study NCT03026738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene mesh
Description: A strip of polypropylene mesh will be introduced and sutured.
Study NCT04304456 — intervention group
Intervention type: OTHER
Intervention: Treatment
Description: Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
Study NCT02227576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT02728427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization using central venous catheter(CVC-2 7F)
Description: Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
Study NCT02321969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE (green tea extract)
Description: 6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
Study NCT02728427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral catheterization using Foley catheter
Description: Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
Study NCT00096161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00096161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00096161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV
Study NCT01418508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low protein diet plus α-keto acid
Description: low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
Study NCT01418508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: very low protein diet plus α-keto acid
Description: very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
Study NCT02762227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal high resolution CT
Description: CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
Study NCT02762227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Description: CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
Study NCT02762227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
Study NCT03849573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OncoTool Intervention (MBSR + HT education)
Description: OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT03849573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncotool Control (health +HT education)
Description: OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT00947505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb 2009, 7 Beam
Description: Device application 3 times week (non-consecutive days), for 26 weeks
Study NCT00947505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week (non-consecutive days), for 26 weeks
Study NCT00096161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study NCT02015221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression Device
Description: A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
Study NCT02015221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression Garments
Description: Compression stockings with a 30-40mmHg level of compression.
Study NCT03894371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermage FLX
Description: Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
Study NCT00322972 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mass treatment with oral azithromycin to an entire community
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study NCT00322972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mass treatment with oral azithromycin to an entire community
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study NCT00995566 — intervention group
Intervention type: DRUG
Intervention: Sitaxentan sodium
Description: Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
Study NCT02411747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing
Study NCT02411747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directed self-regulated simulation training
Study NCT02411747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directed self-regulated simulation training
Study NCT03717272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0117
Description: AEF0117 capsules
Study NCT03717272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AEF0117
Description: AEF0117 capsules
Study NCT03717272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study NCT03158220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
Study NCT03158220 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V503
Description: V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
Study NCT03155646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
Study NCT03155646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
Study NCT03717272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study NCT00167856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venalafaxine hydrochloride
Description: Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
Study NCT00167856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venalafaxine hydrochloride
Description: Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
Study NCT06421129 — intervention group
Intervention type: PROCEDURE
Intervention: anal fistula surgery
Description: anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
Study NCT00368290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 300mg a day for 8 weeks
Study NCT00368290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills for 8 weeks
Study NCT00368290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
Study NCT00368290 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
Study NCT02727231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence D2A or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
Study NCT02727231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
Study NCT04240080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein® Veinfinder
Description: Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
Study NCT01150344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone (atovaquone + proguanil combination)
Description: 4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
Study NCT01150344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RIAMET (artemether + LUMEFANTRIN combination)
Description: 4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
Study NCT02979860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration 90 min
Description: Sleep duration: time in bed increased by 90 minutes
Study NCT02979860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration 45 min
Description: Sleep duration: time in bed increased by 45 minutes
Study NCT02979860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep timing
Description: Sleep timing: bed time kept consistent
Study NCT02615626 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical Periodontal Treatment.
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
Study NCT03320876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib
Description: one filgotinib oral tablet once daily.
Study NCT02874170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spectroscopy magnetic resonance of phosphorus 31
Study NCT02874170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectroscopy magnetic resonance of phosphorus 31
Study NCT01816451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running training
Description: The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
Study NCT00002501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT03508791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arterial carbon dioxide monitoring
Description: Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
Study NCT03508791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-tidal carbon dioxide monitoring
Description: End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
Study NCT03508791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide monitoring
Description: Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
Study NCT02226744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focused Breathing
Study NCT00755300 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of total thrombolic load
Description: A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
Study NCT03712709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Truenat MTB
Description: The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
Study NCT04140123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: ZSP1601 tablets be taken orally for 28 days.
Study NCT04140123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601
Study NCT04140123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601
Study NCT01587768 — intervention group
Intervention type: DRUG
Intervention: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
Study NCT00401388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
Study NCT00401388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
Study NCT00401388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
Study NCT00401388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetics
Description: Antiemetic prophylaxis will be administered at the treating investigator's discretion.
Study NCT00950677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta (exenatide)
Description: exenatide 5 mcg subcutaneously
Study NCT03155646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
Study NCT02481505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1%
Description: Intrathecal Route
Study NCT00950677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symlin (pramlintide)
Description: pramlintide 60 mcg subcutaneously
Study NCT02525549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Gel
Study NCT02525549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene and Benzoyl Peroxide Gel (Reference)
Study NCT02525549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel